IM PHARMA
ActiveSummary
IM PHARMA has been active since 2009 and the Belgian State Gazette contains no insolvency or warning signals. The 2024 annual accounts show equity of €817k and a net result of €142k. Equity is growing by ~6.4% per year across the filed fiscal years. Its solvency ranks better than 81% of 9624 sector peers (fiscal year 2024). The computed 12-month bankruptcy probability is 0.7% (low).
Checked score
Score 2024
Axes · tick = 2023
Profitability84=
Solvency94▼-2
Growth78=
Track record100
Bankruptcy probability, 12 months
0.7%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €65k at 30 days acceptable
Liquidity ample (current ratio 2.6 against 2.82 in 2023; short-term debt: 29.8% and cash: 30.3% of total assets), and 30.9% of the assets are financed with debt.
Credit check for your own amount and term
Signals
Four signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Retail trade (NACE 47)
about 45% more bankruptcies
← fewer bankruptcies
more bankruptcies →
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2024Solvency, return and age of the figures
Solvency
69.1%
Return on assets
12%
Age of the figures
21 mo
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 31-07-2025, 0 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
not confirmed
2024
on the day
2023
on the day
2022
3 d early
2021
4 d early
2020
11 d early
2019
17 d early
← before the deadline
after the deadline →
Checked, nothing found (1)
Financials · fiscal year 2024, abbreviated schema
Equity
€817k▲ 8.1%
2023 · €756k
2018: €564k
2019: €645k▲ +14.4% vs 2018
2020: €561k▼ -12.9% vs 2019lowest in 7 years
2021: €651k▲ +16.0% vs 2020
2022: €738k▲ +13.3% vs 2021
2023: €756k▲ +2.4% vs 2022
2024: €817k▲ +8.1% vs 2023highest in 7 years
2018 → 2024
Total assets
€1.18M▲ 11.4%
2023 · €1.06M
2018: €1.03Mlowest in 7 years
2019: €1.14M▲ +10.7% vs 2018
2020: €1.05M▼ -8.0% vs 2019
2021: €1.14M▲ +8.7% vs 2020
2022: €1.03M▼ -9.2% vs 2021
2023: €1.06M▲ +2.7% vs 2022
2024: €1.18M▲ +11.4% vs 2023highest in 7 years
2018 → 2024
Net result
€142k▲ 13.4%
2023 · €125k
2018: €108k
2019: €81k▼ -24.7% vs 2018lowest in 7 years
2020: €115k▲ +42.3% vs 2019
2021: €148k▲ +27.8% vs 2020highest in 7 years
2022: €145k▼ -1.9% vs 2021
2023: €125k▼ -13.5% vs 2022
2024: €142k▲ +13.4% vs 2023
2018 → 2024
Working capital
€563k▲ 12.8%
2023 · €499k
2018: €551k
2019: €498k▼ -9.7% vs 2018
2020: €289k▼ -42.0% vs 2019lowest in 7 years
2021: €367k▲ +26.9% vs 2020
2022: €466k▲ +27.2% vs 2021
2023: €499k▲ +7.1% vs 2022
2024: €563k▲ +12.8% vs 2023highest in 7 years
2018 → 2024
Trend over the years
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20202021202220232024Trend
Equity€561k-€651k▲ 16.0%€738k▲ 13.3%€756k▲ 2.4%€817k▲ 8.1%
2020: €561klowest in 5 years
2021: €651k▲ +16.0% vs 2020
2022: €738k▲ +13.3% vs 2021
2023: €756k▲ +2.4% vs 2022
2024: €817k▲ +8.1% vs 2023highest in 5 years
Operating result€168k-€220k▲ 31.2%€208k▼ 5.6%€186k▼ 10.8%€205k▲ 10.5%
2020: €168klowest in 5 years
2021: €220k▲ +31.2% vs 2020highest in 5 years
2022: €208k▼ -5.6% vs 2021
2023: €186k▼ -10.8% vs 2022
2024: €205k▲ +10.5% vs 2023
Net result€115k-€148k▲ 27.8%€145k▼ 1.9%€125k▼ 13.5%€142k▲ 13.4%
2020: €115klowest in 5 years
2021: €148k▲ +27.8% vs 2020highest in 5 years
2022: €145k▼ -1.9% vs 2021
2023: €125k▼ -13.5% vs 2022
2024: €142k▲ +13.4% vs 2023
Turnover and EBIT margin not published: the abbreviated schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result recovers in 2024; 2024 is 11% above 2023.
Balance-sheet composition
2024 in colour, 2023 as the grey bar beneath
Assets €1.18M
Fixed assets
€266k ▼ 7.2%
Current assets
€915k ▲ 18.4%
Equity and liabilities €1.18M
Equity
€817k ▲ 8.1%
Debt
€365k ▲ 19.9%
Debt's share of the balance-sheet total rises from 28.7% to 30.9%. Equity and debt are higher.
Key figures and ratios
EBITDA
€229k▲
2023 · €221k
Cash flow
€166k▲
2023 · €161k
Current ratio
2.60▼
2023 · 2.82
Quick ratio
2.25▼
2023 · 2.40
Debt to equity
0.45▲
2023 · 0.40
ROE
17.4%▲
2023 · 16.6%
ROA
12.0%▲
2023 · 11.8%
Interest coverage
32.92▼
2023 · 47.37
Debt ≤ 1 year
€352k▲
2023 · €274k
Debt > 1 year
€9k▼
2023 · €28k
Income taxes
€64k▲
2023 · €58k
Staff costs
€59k▲
2023 · €55k
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Filed annual accounts As filed with the NBB · 2024 against 2023 · 54 lines
Balance sheet
Code20232024
Assets
Total assets20/58€1.06M€1.18M▲
Fixed assets21/28€287k€266k▼
Tangible fixed assets22/27€287k€266k▼
Land and buildings22€244k€233k▼
Plant, machinery and equipment23€651€1k▲
Other tangible fixed assets26€43k€33k▼
Current assets29/58€773k€915k▲
Stocks and contracts in progress3€115k€124k▲
Stocks30/36€115k€124k▲
Amounts receivable within one year40/41€96k€100k▲
Trade receivables40€96k€100k▲
Other amounts receivable41€74€46▼
Current investments50/53€200k€330k▲
Cash at bank and in hand54/58€360k€358k▼
Deferred charges and accrued income490/1€1k€3k▲
Equity and liabilities
Total equity and liabilities10/49€1.06M€1.18M▲
Equity10/15€756k€817k▲
Contributions10/11€19k€19k=
Reserves13€737k€798k▲
Distributable reserves133€737k€798k▲
Profit (loss) carried forward14-€0
Amounts payable17/49€304k€365k▲
Amounts payable after more than one year17€28k€9k▼
Financial debts170/4€28k€9k▼
Amounts payable within one year42/48€274k€352k▲
Current portion of amounts payable after more than one year42€21k€19k▼
Trade debts44€68k€76k▲
Suppliers440/4€68k€76k▲
Taxes, remuneration and social security45€41k€36k▼
Taxes450/3€30k€24k▼
Remuneration and social security454/9€12k€13k▲
Other amounts payable47/48€143k€221k▲
Accrued charges and deferred income492/3€2k€4k▲
Income statement
Code20232024
Remuneration, social security and pensions62€55k€59k▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€36k€24k▼
Other operating charges640/8€7k€6k▼
Non-recurring operating charges66A-€264
Gross operating margin9900€283k€294k▲
Operating profit (loss)9901€186k€205k▲
Financial income75/76B€2k€8k▲
Recurring financial income75€2k€8k▲
Financial charges65/66B€5k€7k▲
Recurring financial charges65€5k€7k▲
Profit (loss) for the period before taxes9903€183k€206k▲
Income taxes67/77€58k€64k▲
Profit (loss) for the period9904€125k€142k▲
Profit (loss) for the period to be appropriated9905€125k€142k▲
Appropriation of the result
Profit (loss) to be appropriated9906€125k€142k▲
Transfer from equity791/2€108k€81k▼
Transfer to equity691/2€125k€142k▲
To other reserves6921€125k€142k▲
Profit to be distributed694/7€108k€81k▼
Return on contributions (dividend)694€108k€81k▼
Social balance
Average headcount (FTE)90870.70.7=
The notes to these accounts (21 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Accounts by statement
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Non-recurring operating income76A | - | €2k | - | - | - | - |
| Remuneration, social security and pensions62 | - | €44k | €38k | €55k | €59k | ▲ 6.7% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €54k | €45k | €40k | €36k | €24k | ▼ 33.4% |
| Other operating charges640/8 | - | €4k | €5k | €7k | €6k | ▼ 6.9% |
| Non-recurring operating charges66A | - | - | - | - | €264 | - |
| Gross operating margin9900 | €273k | €314k | €291k | €283k | €294k | ▲ 3.9% |
| Operating profit (loss)9901 | €168k | €220k | €208k | €186k | €205k | ▲ 10.5% |
| Financial income75/76B | - | €2k | €10k | €2k | €8k | ▲ 241% |
| Recurring financial income75 | €3k | €2k | €10k | €2k | €8k | ▲ 241% |
| Financial charges65/66B | - | €8k | €5k | €5k | €7k | ▲ 48.8% |
| Recurring financial charges65 | €8k | €8k | €5k | €5k | €7k | ▲ 48.8% |
| Profit (loss) for the period before taxes9903 | €158k | €215k | €212k | €183k | €206k | ▲ 12.4% |
| Income taxes67/77 | €43k | €67k | €68k | €58k | €64k | ▲ 10.1% |
| Profit (loss) for the period9904 | €115k | €148k | €145k | €125k | €142k | ▲ 13.4% |
| Profit (loss) for the period to be appropriated9905 | €115k | €148k | €145k | €125k | €142k | ▲ 13.4% |
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €1.05M | €1.14M | €1.03M | €1.06M | €1.18M | ▲ 11.4% |
| Fixed assets21/28 | €400k | €363k | €323k | €287k | €266k | ▼ 7.2% |
| Tangible fixed assets22/27 | €400k | €363k | €323k | €287k | €266k | ▼ 7.2% |
| Land and buildings22 | - | €266k | €255k | €244k | €233k | ▼ 4.5% |
| Plant, machinery and equipment23 | - | €2k | €1k | €651 | €1k | ▲ 62.9% |
| Furniture and vehicles24 | - | €24k | €12k | - | - | - |
| Other tangible fixed assets26 | - | €71k | €55k | €43k | €33k | ▼ 23.9% |
| Current assets29/58 | €646k | €775k | €709k | €773k | €915k | ▲ 18.4% |
| Stocks and contracts in progress3 | €117k | €114k | €114k | €115k | €124k | ▲ 7.2% |
| Stocks30/36 | - | €114k | €114k | €115k | €124k | ▲ 7.2% |
| Amounts receivable within one year40/41 | €81k | €73k | €102k | €96k | €100k | ▲ 4.8% |
| Trade receivables40 | - | €73k | €102k | €96k | €100k | ▲ 4.8% |
| Other amounts receivable41 | - | - | €431 | €74 | €46 | ▼ 37.3% |
| Current investments50/53 | - | - | €100k | €200k | €330k | ▲ 64.9% |
| Cash at bank and in hand54/58 | €446k | €585k | €390k | €360k | €358k | ▼ 0.6% |
| Deferred charges and accrued income490/1 | - | €3k | €3k | €1k | €3k | ▲ 129% |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €1.05M | €1.14M | €1.03M | €1.06M | €1.18M | ▲ 11.4% |
| Equity10/15 | €561k | €651k | €738k | €756k | €817k | ▲ 8.1% |
| Contributions10/11 | - | €19k | €19k | €19k | €19k | = |
| Reserves13 | €543k | €633k | €720k | €737k | €798k | ▲ 8.3% |
| Non-distributable reserves130/1 | - | €2k | €2k | - | - | - |
| Reserves not available under the articles1311 | - | €2k | €2k | - | - | - |
| Distributable reserves133 | - | €631k | €718k | €737k | €798k | ▲ 8.3% |
| Profit (loss) carried forward14 | - | - | - | - | €0 | - |
| Amounts payable17/49 | €485k | €486k | €294k | €304k | €365k | ▲ 19.9% |
| Amounts payable after more than one year17 | €128k | €75k | €49k | €28k | €9k | ▼ 68.6% |
| Financial debts170/4 | - | €75k | €49k | €28k | €9k | ▼ 68.6% |
| Amounts payable within one year42/48 | €358k | €408k | €243k | €274k | €352k | ▲ 28.6% |
| Current portion of amounts payable after more than one year42 | - | €49k | €26k | €21k | €19k | ▼ 7.3% |
| Trade debts44 | €41k | €52k | €76k | €68k | €76k | ▲ 11.5% |
| Suppliers440/4 | - | €52k | €76k | €68k | €76k | ▲ 11.5% |
| Taxes, remuneration and social security45 | - | €58k | €32k | €41k | €36k | ▼ 12.9% |
| Taxes450/3 | - | €51k | €27k | €30k | €24k | ▼ 20.2% |
| Remuneration and social security454/9 | - | €7k | €5k | €12k | €13k | ▲ 5.3% |
| Other amounts payable47/48 | - | €248k | €110k | €143k | €221k | ▲ 53.9% |
| Accrued charges and deferred income492/3 | - | €3k | €2k | €2k | €4k | ▲ 57.9% |
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €115k | €148k | €145k | €125k | €142k | ▲ 13.4% |
| + Depreciation and write-downs630 | €54k | €45k | €40k | €36k | €24k | ▼ 33.4% |
| Operating cash flow (approximation) | €169k | €193k | €184k | €161k | €166k | ▲ 3.0% |
| Investment in fixed assets (approximation) | - | €-7k | €0 | €0 | €-3k | - |
| Change in cash | - | €139k | €-195k | €-30k | €-2k | ▲ 92.4% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
2025
31-07
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
2024
31-07
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema
2023
28-07
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema
2022
27-07
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema
2021
31-12
Financial
Highest result since 2018net €148k ▲27.8%
Operating result €220k, net result €148k, both a record.
20-07
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema
2020
14-07
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema
2019
31-12
Financial
Weakest financial yearnet €81k ▼24.7%
Net result drops to €81k, the lowest in the series; recovery starts the following year.
12-07
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema
2018
16-07
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema
2017
10-07
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema
2016
23-06
NBB filing
Annual accounts filed
fiscal year 2015 · abbreviated schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 2 acts read
About the unread acts
We know of 2 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
2 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Ichtegem · 1 establishment unit since 2009
Ground area
2,106 m²
Building footprint
337 m²
Volume, LiDAR
1,456 m³
Parcel 35006A0562/00F000, Flanders · tallest building 8.3 m, ±2 floors. Linked by address, not a title deed.
1 establishment unit
IM Pharma
since 20092.179.493.196
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 35006A0562/00F000 | Flanders | 2,106 m² | 2 · 337 m² | 8.3 m · 2 fl. |
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
Farma Danaux
BE 1002.124.222
Wetteren · Eq €817,167
MAST & CO
BE 0839.457.596
Merchtem · Eq €817,461
Apotheek Macharis
BE 0874.337.709
Dendermonde · Eq €817,612
APOTHEEK VANHAESENDONCK
BE 0890.607.280
Steenokkerzeel · Eq €815,146
MAHO
BE 0812.300.665
Tienen · Eq €817,913
Of 5,220 companies in sector 47730 we hold annual accounts for 3,861. 3,150 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPrivate limited company
Founded26-06-2009
Fiscal year end31-12
Activities, NACEBEL 2025
47730Retail sale of pharmaceutical products
Scores and ratios are computed by Checked and are not a credit decision.